PubRank

Douglas W Grosenbach

Author PubWeight™ 23.07‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J Clin Oncol 2004 3.11
2 A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res 2006 2.20
3 IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. Blood 2007 2.01
4 Clinical safety of a viral vector based prostate cancer vaccine strategy. J Urol 2007 1.84
5 Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer. J Urol 2005 1.59
6 Vaccine therapy of established tumors in the absence of autoimmunity. Clin Cancer Res 2003 1.44
7 Costimulatory molecules as adjuvants for immunotherapy. Front Biosci 2006 1.37
8 Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge. J Virol 2008 1.22
9 Vaccines with enhanced costimulation maintain high avidity memory CTL. J Immunol 2005 1.12
10 ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. Antimicrob Agents Chemother 2009 1.07
11 A novel inhibitor of dengue virus replication that targets the capsid protein. Antimicrob Agents Chemother 2012 1.02
12 Novel benzoxazole inhibitor of dengue virus replication that targets the NS3 helicase. Antimicrob Agents Chemother 2013 0.91
13 TRICOM vector based cancer vaccines. Curr Pharm Des 2006 0.87
14 Efficacy of tecovirimat (ST-246) in nonhuman primates infected with variola virus (Smallpox). Antimicrob Agents Chemother 2013 0.85
15 Impact of ST-246® on ACAM2000™ smallpox vaccine reactogenicity, immunogenicity, and protective efficacy in immunodeficient mice. Vaccine 2010 0.84
16 Vector-based delivery of tumor-associated antigens and T-cell co-stimulatory molecules in the induction of immune responses and anti-tumor immunity. Cancer Detect Prev 2002 0.76
17 Effects of postchallenge administration of ST-246 on dissemination of IHD-J-Luc vaccinia virus in normal mice and in immune-deficient mice reconstituted with T cells. J Virol 2013 0.76
18 Antiviral options for biodefense. Curr Opin Virol 2013 0.75